
The New England Journal of Medicine | Research & Review Articles …
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...
Current Issue | New England Journal of Medicine
Nov 27, 2025 · Explore the current issue of The New England Journal of Medicine (Vol. 393 No. 21).
Recently Published - The New England Journal of Medicine
Nov 29, 2025 · Explore this issue of The New England Journal of Medicine (Vol. 0 No. 0).
About NEJM - The New England Journal of Medicine
The New England Journal of Medicine (NEJM) is recognized as the world’s leading medical journal and website. Published continuously for over 200 years, NEJM delivers high-quality, …
Tirzepatide as Compared with Semaglutide for the Treatment of …
May 11, 2025 · Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults …
Extended Reduced-Dose Apixaban for Cancer-Associated Venous ...
Mar 29, 2025 · In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant is effective in preventing recurrent …
NEJM Author Center
NEJM seeks submissions of original research, reviews, case reports, and commentaries that improve patient care and clinical practice, or that offer new information about the biology of …
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer …
Jun 1, 2025 · Methods In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate …
Perioperative Durvalumab in Gastric and Gastroesophageal …
Jun 1, 2025 · Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) is a standard therapy for resectable gastric and gastroesophageal junction adenocarcinomas, but …
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in …
Sep 15, 2024 · Previous results from this trial showed longer overall survival after treatment with nivolumab plus ipilimumab or with nivolumab monotherapy than with ipilimumab monotherapy …